Do analysts recommend TPST or IMMP?

Prima BioMed has a consensus target price of $5.50, suggesting a potential upside of 1,347.37%. Given Prima BioMed's stronger consensus rating and higher probable upside, analysts clearly believe Prima BioMed is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, TPST or IMMP?

Tempest Therapeutics has higher earnings, but lower revenue than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tempest Therapeutics N/A N/A -$26.26M -$4.28 N/A Prima BioMed $6.69M 8.37 -$39.78M N/A N/A

Is TPST or IMMP more profitable?

Prima BioMed's return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -398.35% -123.00% Prima BioMed N/A N/A N/A

Does the media prefer TPST or IMMP?

In the previous week, Tempest Therapeutics had 2 more articles in the media than Prima BioMed. MarketBeat recorded 5 mentions for Tempest Therapeutics and 3 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.21 beat Tempest Therapeutics' score of 0.17 indicating that Prima BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tempest Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate INMB or TPST?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is INMB or TPST more profitable?

INmune Bio's return on equity of -82.87% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% Tempest Therapeutics N/A -398.35% -123.00%

Does the media refer more to INMB or TPST?

In the previous week, Tempest Therapeutics had 2 more articles in the media than INmune Bio. MarketBeat recorded 5 mentions for Tempest Therapeutics and 3 mentions for INmune Bio. INmune Bio's average media sentiment score of 0.31 beat Tempest Therapeutics' score of 0.17 indicating that INmune Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tempest Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer INO or TPST?

Inovio Pharmaceuticals currently has a consensus price target of $3.17, indicating a potential upside of 190.52%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Inovio Pharmaceuticals is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inovio Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is INO or TPST more profitable?

Tempest Therapeutics' return on equity of -398.35% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Inovio Pharmaceuticals N/A -669.94% -73.97% Tempest Therapeutics N/A -398.35% -123.00%

Does the media favor INO or TPST?

In the previous week, Inovio Pharmaceuticals had 11 more articles in the media than Tempest Therapeutics. MarketBeat recorded 16 mentions for Inovio Pharmaceuticals and 5 mentions for Tempest Therapeutics. Inovio Pharmaceuticals' average media sentiment score of 0.72 beat Tempest Therapeutics' score of 0.17 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tempest Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer INKT or TPST?

MiNK Therapeutics currently has a consensus price target of $35.00, suggesting a potential upside of 210.56%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe MiNK Therapeutics is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher valuation and earnings, INKT or TPST?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A Tempest Therapeutics N/A N/A -$26.26M -$4.28 N/A

Is INKT or TPST more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -86.10% Tempest Therapeutics N/A -398.35% -123.00%

Does the media favor INKT or TPST?

In the previous week, MiNK Therapeutics had 7 more articles in the media than Tempest Therapeutics. MarketBeat recorded 12 mentions for MiNK Therapeutics and 5 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 0.17 beat MiNK Therapeutics' score of -0.45 indicating that Tempest Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Tempest Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend TCRX or TPST?

TScan Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 670.42%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe TScan Therapeutics is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer TCRX or TPST?

In the previous week, TScan Therapeutics had 12 more articles in the media than Tempest Therapeutics. MarketBeat recorded 17 mentions for TScan Therapeutics and 5 mentions for Tempest Therapeutics. TScan Therapeutics' average media sentiment score of 0.48 beat Tempest Therapeutics' score of 0.17 indicating that TScan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Tempest Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Tempest Therapeutics (TPST) Competitors

$1.01 -0.16 (-13.25%)

Closing price 04:00 PM Eastern

Extended Trading

$1.06 +0.04 (+4.04%)

As of 07:52 PM Eastern

Compare

TPST vs. IMMP, INMB, INO, INKT, and TCRX

Should you buy Tempest Therapeutics stock or one of its competitors? Tempest Therapeutics's main competitors and comparable companies include Prima BioMed (IMMP), INmune Bio (INMB), Inovio Pharmaceuticals (INO), MiNK Therapeutics (INKT), and TScan Therapeutics (TCRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tempest Therapeutics compare to Prima BioMed?

Tempest Therapeutics (NASDAQ:TPST) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

In the previous week, Tempest Therapeutics had 2 more articles in the media than Prima BioMed. MarketBeat recorded 5 mentions for Tempest Therapeutics and 3 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.21 beat Tempest Therapeutics' score of 0.17 indicating that Prima BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempest Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prima BioMed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 36.2% of Tempest Therapeutics shares are held by company insiders. Comparatively, 3.1% of Prima BioMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Prima BioMed's return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-398.35%	-123.00%
Prima BioMed	N/A	N/A	N/A

Prima BioMed has a consensus target price of $5.50, suggesting a potential upside of 1,347.37%. Given Prima BioMed's stronger consensus rating and higher probable upside, analysts clearly believe Prima BioMed is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Tempest Therapeutics has a beta of -1.72, suggesting that its share price is 272% less volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market.

Tempest Therapeutics has higher earnings, but lower revenue than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A
Prima BioMed	$6.69M	8.37	-$39.78M	N/A	N/A

Summary

Prima BioMed beats Tempest Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Tempest Therapeutics compare to INmune Bio?

INmune Bio (NASDAQ:INMB) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Tempest Therapeutics had 2 more articles in the media than INmune Bio. MarketBeat recorded 5 mentions for Tempest Therapeutics and 3 mentions for INmune Bio. INmune Bio's average media sentiment score of 0.31 beat Tempest Therapeutics' score of 0.17 indicating that INmune Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tempest Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tempest Therapeutics has lower revenue, but higher earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,204.35	-$45.93M	-$0.67	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A

INmune Bio has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.72, suggesting that its stock price is 272% less volatile than the broader market.

INmune Bio's return on equity of -82.87% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Tempest Therapeutics	N/A	-398.35%	-123.00%

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by insiders. Comparatively, 36.2% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

INmune Bio beats Tempest Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Tempest Therapeutics compare to Inovio Pharmaceuticals?

Inovio Pharmaceuticals (NASDAQ:INO) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Inovio Pharmaceuticals currently has a consensus price target of $3.17, indicating a potential upside of 190.52%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Inovio Pharmaceuticals is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Tempest Therapeutics' return on equity of -398.35% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%
Tempest Therapeutics	N/A	-398.35%	-123.00%

Tempest Therapeutics has lower revenue, but higher earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,878.43	-$84.95M	-$1.45	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A

Inovio Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.72, suggesting that its stock price is 272% less volatile than the broader market.

In the previous week, Inovio Pharmaceuticals had 11 more articles in the media than Tempest Therapeutics. MarketBeat recorded 16 mentions for Inovio Pharmaceuticals and 5 mentions for Tempest Therapeutics. Inovio Pharmaceuticals' average media sentiment score of 0.72 beat Tempest Therapeutics' score of 0.17 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tempest Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 36.2% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Inovio Pharmaceuticals beats Tempest Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Tempest Therapeutics compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

MiNK Therapeutics currently has a consensus price target of $35.00, suggesting a potential upside of 210.56%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe MiNK Therapeutics is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

MiNK Therapeutics has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.72, suggesting that its share price is 272% less volatile than the broader market.

MiNK Therapeutics' return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-86.10%
Tempest Therapeutics	N/A	-398.35%	-123.00%

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by insiders. Comparatively, 36.2% of Tempest Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, MiNK Therapeutics had 7 more articles in the media than Tempest Therapeutics. MarketBeat recorded 12 mentions for MiNK Therapeutics and 5 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 0.17 beat MiNK Therapeutics' score of -0.45 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Tempest Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MiNK Therapeutics beats Tempest Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Tempest Therapeutics compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

In the previous week, TScan Therapeutics had 12 more articles in the media than Tempest Therapeutics. MarketBeat recorded 17 mentions for TScan Therapeutics and 5 mentions for Tempest Therapeutics. TScan Therapeutics' average media sentiment score of 0.48 beat Tempest Therapeutics' score of 0.17 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Tempest Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TScan Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 670.42%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe TScan Therapeutics is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Tempest Therapeutics has lower revenue, but higher earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	4.93	-$129.77M	-$0.96	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A

Tempest Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. TScan Therapeutics' return on equity of -108.72% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
Tempest Therapeutics	N/A	-398.35%	-123.00%

TScan Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.72, meaning that its stock price is 272% less volatile than the broader market.

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by insiders. Comparatively, 36.2% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

TScan Therapeutics beats Tempest Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Tempest Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TPST vs. The Competition

Export

Metric	Tempest Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.70M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-0.24	6.29	211.09	21.74
Price / Sales	N/A	1,295.89	602.98	92.99
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	0.75	16.78	12.91	6.24
Net Income	-$26.26M	-$13.32M	$3.45B	$347.60M
7 Day Performance	10.72%	1.74%	1.12%	1.07%
1 Month Performance	3.52%	1.60%	1.79%	1.03%
1 Year Performance	-89.29%	56.43%	67.69%	20.77%

Tempest Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TPST Tempest Therapeutics	1.5387 of 5 stars	$1.02 -13.2%	N/A	-87.5%	$18.70M	N/A	N/A	20	News Coverage Earnings Report Gap Down
IMMP Prima BioMed	3.0158 of 5 stars	$0.38 -0.4%	$5.50 +1,331.9%	-76.7%	$56.86M	$6.69M	N/A	2,021	News Coverage Positive News Short Interest Decrease
INMB INmune Bio	0.7466 of 5 stars	$2.12 +1.4%	N/A	-18.8%	$55.43M	$50K	N/A	10
INO Inovio Pharmaceuticals	3.2927 of 5 stars	$0.74 +10.2%	$3.25 +341.3%	-47.1%	$54.96M	$60K	N/A	320	News Coverage Earnings Report Analyst Upgrade Analyst Revision Gap Up
INKT MiNK Therapeutics	2.7104 of 5 stars	$10.95 flat	$35.00 +219.6%	-37.1%	$54.55M	N/A	N/A	30	Trending News Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TPST) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tempest Therapeutics (TPST) Competitors

TPST vs. IMMP, INMB, INO, INKT, and TCRX

How does Tempest Therapeutics compare to Prima BioMed?

Summary

How does Tempest Therapeutics compare to INmune Bio?

Summary

How does Tempest Therapeutics compare to Inovio Pharmaceuticals?

Summary

How does Tempest Therapeutics compare to MiNK Therapeutics?

Summary

How does Tempest Therapeutics compare to TScan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tempest Therapeutics (TPST) Competitors

TPST vs. IMMP, INMB, INO, INKT, and TCRX

How does Tempest Therapeutics compare to Prima BioMed?

Does the media prefer TPST or IMMP?

Do institutionals & insiders hold more shares of TPST or IMMP?

Is TPST or IMMP more profitable?

Do analysts recommend TPST or IMMP?

Which has more volatility and risk, TPST or IMMP?

Which has stronger earnings & valuation, TPST or IMMP?

Summary

How does Tempest Therapeutics compare to INmune Bio?

Do analysts rate INMB or TPST?

Does the media refer more to INMB or TPST?

Which has higher valuation and earnings, INMB or TPST?

Which has more risk and volatility, INMB or TPST?

Is INMB or TPST more profitable?

Do institutionals and insiders believe in INMB or TPST?

Summary

How does Tempest Therapeutics compare to Inovio Pharmaceuticals?

Do analysts prefer INO or TPST?

Is INO or TPST more profitable?

Which has stronger valuation and earnings, INO or TPST?

Which has more volatility and risk, INO or TPST?

Does the media favor INO or TPST?

Do institutionals and insiders have more ownership in INO or TPST?

Summary

How does Tempest Therapeutics compare to MiNK Therapeutics?

Do analysts prefer INKT or TPST?

Which has more volatility & risk, INKT or TPST?

Is INKT or TPST more profitable?

Which has higher valuation and earnings, INKT or TPST?

Do institutionals & insiders hold more shares of INKT or TPST?

Does the media favor INKT or TPST?

Summary

How does Tempest Therapeutics compare to TScan Therapeutics?

Does the media prefer TCRX or TPST?

Do analysts recommend TCRX or TPST?

Which has better earnings & valuation, TCRX or TPST?

Is TCRX or TPST more profitable?

Which has more volatility and risk, TCRX or TPST?

Do insiders & institutionals hold more shares of TCRX or TPST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools